Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Ambry Genetics | RCV000561568 | SCV000662522 | uncertain significance | Hereditary cancer-predisposing syndrome | 2016-09-29 | criteria provided, single submitter | clinical testing | Lines of evidence used in support of classification: Insufficient evidence,In silico models in agreement (benign) |
Color | RCV000561568 | SCV000908362 | uncertain significance | Hereditary cancer-predisposing syndrome | 2018-05-09 | criteria provided, single submitter | clinical testing | |
Invitae | RCV000792707 | SCV000932017 | uncertain significance | Hereditary nonpolyposis colon cancer | 2018-12-15 | criteria provided, single submitter | clinical testing | This sequence change replaces proline with leucine at codon 320 of the MSH6 protein (p.Pro320Leu). The proline residue is moderately conserved and there is a moderate physicochemical difference between proline and leucine. This variant is present in population databases (rs779022657, ExAC 0.002%). This variant has not been reported in the literature in individuals with MSH6-related disease. ClinVar contains an entry for this variant (Variation ID: 479932). Algorithms developed to predict the effect of missense changes on protein structure and function are either unavailable or do not agree on the potential impact of this missense change (SIFT: "Deleterious"; PolyPhen-2: "Benign"; Align-GVGD: "Class C0"). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |